Open AccessEfficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis
Author(s) -
Lawrence F. Eichenfield,
Carsten Flohr,
Robert Sidbury,
Elaine C. Siegfried,
Zsuzsanna Szalai,
Ryszard Galus,
Zhirong Yao,
Hidetoshi Takahashi,
S. Barbarot,
Claire Feeney,
Fan Zhang,
Marco DiBonaventura,
Ricardo Rojo,
Hernán Valdez,
Gary Chan
Publication year - 2021
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2021.2830
Subject(s) - medicine , eczema area and severity index , atopic dermatitis , placebo , adverse effect , randomized controlled trial , clinical endpoint , pediatrics , dermatology , alternative medicine , pathology
Dupilumab subcutaneous injection is approved for treating moderate-to-severe atopic dermatitis (AD) in adolescents, but there has been too little research on an efficacious systemic oral treatment with a favorable benefit-risk profile for adolescents with moderate-to-severe AD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom